Found: 4
Select item for more details and to access through your institution.
Inpatient Admissions and Re-Admissions in Medicare Beneficiaries Initiating Umeclidinium/Vilanterol or Tiotropium Therapy.
- Published in:
- International Journal of COPD, 2024, v. 19, p. 439, doi. 10.2147/COPD.S436654
- By:
- Publication type:
- Article
Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States
- Published in:
- International Journal of COPD, 2024, v. 19, p. 97, doi. 10.2147/COPD.S424497
- By:
- Publication type:
- Article
Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US.
- Published in:
- Journal of Asthma & Allergy, 2023, v. 16, p. 1309, doi. 10.2147/JAA.S424055
- By:
- Publication type:
- Article
Changes in Oral Corticosteroid Utilization in Patients with COPD Following Initiation of FF/UMEC/VI.
- Published in:
- International Journal of COPD, 2023, v. 18, p. 2367, doi. 10.2147/COPD.S419272
- By:
- Publication type:
- Article